Search

Moshe A Arditi

from Encino, CA
Age ~68
Get Report
Also known as:
Moshe D Arditi, Mose Arditi, Moshe Ardit, Roiti A Moshe
Phone and address:
4210 Hayvenhurst Ave, Van Nuys, CA 91436
(818) 784-1551
Related to:
Andrew V Arditi, 27Rachel Arditi, 29Morton Manning
Connected to:
Haruko K Ardito, 59Leonisa A Ardizzone, 55Sean A Ardizzone, 49Susan C Ardizzone, 57Cole R Ardle, 52James M Ardle, 43John Ardle, 31Diane E Ardner, 74Angela R Ardoin, 42Bridget B Ardoin, 65

Moshe Arditi Phones & Addresses

  • 4210 Hayvenhurst Ave, Encino, CA 91436 (818) 784-1551 (818) 784-2582
  • 4647 Willis Ave, Sherman Oaks, CA 91403
  • Los Angeles, CA
  • Chicago, IL

Work

Company: Los Angeles Office Address: 8700 Beverly Blvd, Los Angeles, CA 90048 Phones: (800) 233-2771 (310) 659-3928

Education

School / High School: Istanbul University / Cerrahpasa Medical Faculty

Languages

English • French

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatric Infectious Disease Medicine, 2002

Specialities

Pediatric Infectious Disease Medicine

Professional Records

Medicine Doctors

Moshe Arditi Photo 1

Dr. Moshe Arditi, Los Angeles CA - MD (Doctor of Medicine)

View page
Specialties:
Pediatric Infectious Disease Medicine
Address:
Los Angeles Office
8700 Beverly Blvd, Los Angeles, CA 90048
(800) 233-2771 (Phone), (310) 659-3928 (Fax)

Cedars-Sinai Med Ctr Ped Infcts
8700 Beverly Blvd Suite 4221, Los Angeles, CA 90048
(310) 423-4471 (Phone)
Certifications:
Pediatric Infectious Disease Medicine, 2002
Pediatrics, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
French
Hospitals:
Los Angeles Office
8700 Beverly Blvd, Los Angeles, CA 90048

Cedars-Sinai Med Ctr Ped Infcts
8700 Beverly Blvd Suite 4221, Los Angeles, CA 90048

Cedars - Sinai Medical Center
8700 West Beverly Boulevard, West Hollywood, CA 90048
Education:
Medical School
Istanbul University / Cerrahpasa Medical Faculty
Medical School
University Of Chicago
Medical School
Chldns Meml Hosp-Northwestern U
Moshe Arditi Photo 2

Moshe Arditi

View page
Specialties:
Pediatric Infectious Diseases
Work:
Cedars Sinai Medical GroupCedars-Sinai Medical Center Pediatric Infectious Disease
8700 Beverly Blvd STE 4221, Los Angeles, CA 90048
(310) 423-4471 (phone), (310) 423-4131 (fax)
Education:
Medical School
Istanbul Univ, Cerrahpasa Tip Fak, Istanbul, Turkey
Graduated: 1980
Languages:
English
Description:
Dr. Arditi graduated from the Istanbul Univ, Cerrahpasa Tip Fak, Istanbul, Turkey in 1980. He works in Los Angeles, CA and specializes in Pediatric Infectious Diseases. Dr. Arditi is affiliated with Cedars-Sinai Medical Center.
Moshe Arditi Photo 3

Moshe Arditi, West Hollywood CA

View page
Specialties:
Pediatrics
Pediatric Infectious Diseases
Infectious Disease
Work:
Cedars-Sinai Medical Center
8700 Beverly Blvd, West Hollywood, CA 90048
Education:
Istanbul Universitesi, Cerrahpasa (1981)
Moshe Arditi Photo 4

Moshe Arditi, West Hollywood CA

View page
Specialties:
Infectious Disease Specialist
Address:
8700 Beverly Blvd, West Hollywood, CA 90048
Education:
Istanbul University, Cerrahpasa Faculty of Medicine - Doctor of Medicine
Children's Memorial Hospital - Fellowship - Pediatric Infectious Diseases (Pediatrics)
Bernard Mitchell Hospital-University of Chicago Hospitals - Residency - Pediatrics
Bernard Mitchell Hospital-University of Chicago Hospitals - Internship - Pediatrics

Business Records

Name / Title
Company / Classification
Phones & Addresses
Moshe Arditi
President
M AND D CONSULTING, INC
4210 Hayvenhurst Ave, Encino, CA 91436
Moshe Arditi
Moshe Arditi MD
Pediatrician
8700 Beverly Blvd, Los Angeles, CA 90048
(310) 423-4471

Publications

Us Patents

Short-Form Human Md-2 As A Negative Regulator Of Toll-Like Receptor 4 Signaling

View page
US Patent:
8546324, Oct 1, 2013
Filed:
Mar 18, 2011
Appl. No.:
13/051390
Inventors:
Moshe Arditi - Encino CA, US
Pearl Gray - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A61K 38/17
C07K 14/47
US Classification:
514 21, 4241981, 530350
Abstract:
The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions.

Methods For Treating Vascular Disease By Inhibiting Toll-Like Receptor-4

View page
US Patent:
20030077279, Apr 24, 2003
Filed:
Apr 23, 2002
Appl. No.:
10/128166
Inventors:
Moshe Arditi - Encino CA, US
Tripathi Rajavashisth - El Camino Village CA, US
Prediman Shah - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER
International Classification:
A61K048/00
A61K039/395
A61M031/00
US Classification:
424/144100, 514/044000, 604/500000
Abstract:
Methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of Toll-like receptor-4 (TLR-4). Also included is an intravascular device coated with a compound that inhibits TLR-4; thereby imparting an improved efficacy to the device. TLR-4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway.

Method Of Treating Inflammation With Hiv-1 Protease Inhibitors And Their Derivatives

View page
US Patent:
20030138423, Jul 24, 2003
Filed:
Nov 27, 2002
Appl. No.:
10/306000
Inventors:
Moshe Arditi - Encino CA, US
Ozlem Equils - Sherman Oaks CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER
International Classification:
A61K039/395
A61K031/415
A61K031/551
US Classification:
424/145100, 514/220000, 514/406000
Abstract:
Disclosed herein are methods of treating inflammation by administering to a patient an HIV-protease inhibitor. While protease inhibitors are known for their capacity to prevent or significantly hinder the cleavage of proteins that would otherwise become smaller viral particles, certain of these inhibitors may also be employed in the treatment of inflammation and diseases in which an inflammatory response is evident. Further methods are directed to the treatment of disease conditions in which it may be advantageous to down-modulate NF- B cell signal transduction.

Methods For Treating Vascular Disease By Inhibiting Myeloid Differentiation Factor 88

View page
US Patent:
20030148986, Aug 7, 2003
Filed:
Dec 12, 2002
Appl. No.:
10/317992
Inventors:
Moshe Arditi - Encino CA, US
Tripathi Rajavashisth - El Camino Village CA, US
Prediman Shah - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A61K048/00
A61M031/00
US Classification:
514/044000, 604/500000
Abstract:
Methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of myeloid differentiation factor 88 (MyD88). Also included is an intravascular device coated with a compound that inhibits MyD88; thereby imparting an improved efficacy to the device. TLR-4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway by affecting the biological activity of MyD88.

Methods For Treating Vascular Disease

View page
US Patent:
20080286285, Nov 20, 2008
Filed:
May 25, 2005
Appl. No.:
11/569241
Inventors:
Moshe Arditi - Encino CA, US
Tripathi Rajavashisth - El Camino Village CA, US
Prediman K. Shah - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 39/395
A61K 35/76
A61F 2/82
A61K 38/17
A61P 9/00
US Classification:
4241581, 4241721, 424 936, 514408, 4241301, 424423, 514 12
Abstract:
Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88). TLR4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway by affecting the biological activity of the TLR4 receptor and/or MyD88.

Use Of Toll-Like Receptor Ligands As Adjuvants To Vaccination Therapy For Brain Tumors

View page
US Patent:
20110104210, May 5, 2011
Filed:
Jun 17, 2009
Appl. No.:
12/995434
Inventors:
Keith L. Black - Los Angeles CA, US
Dwain Morris-Irvin - Los Angeles CA, US
Moshe Arditi - Encino CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 39/00
A61K 35/12
A61P 35/00
A61P 37/04
US Classification:
4242771, 424 9371
Abstract:
Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.

Compositions And Methods For Treating A Covid-19 Infection

View page
US Patent:
20220235119, Jul 28, 2022
Filed:
Jul 14, 2021
Appl. No.:
17/375601
Inventors:
- Pittsburgh PA, US
- Los Angeles CA, US
She Zhang - Pittsburgh PA, US
Rebecca Porritt - Sherman Oaks CA, US
Moshe Arditi - Encino CA, US
International Classification:
C07K 16/12
A61K 39/215
A61P 31/14
Abstract:
Provided herein are methods of treating a COVID-19 infection in a subject, comprising administering to the subject an effective amount of a composition that reduces the superantigen character of SARS-CoV-2 Spike protein. In some embodiments, the compositions are mimetic peptides of the superantigen region. In some embodiments, the compositions are humanized antibodies, such as humanized mAb 6D3, that bind to the superantigen region.

Intracellular Il-1 Alpha Peptide Methods And Compositions

View page
US Patent:
20210060131, Mar 4, 2021
Filed:
Jan 23, 2019
Appl. No.:
16/963421
Inventors:
- Los Angeles CA, US
Moshe ARDITI - Encino CA, US
Gantsetseg TUMURKHUU - Los Angeles CA, US
Janet MARKMAN - Encino CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 38/20
A61P 35/00
A61P 35/04
Abstract:
Described herein are methods and compositions for the treatment of cancer and cancer metastasis. Methods for the reduction or prevention of cancer metastasis are also described. In particular, the present invention discloses the use of the IL-1α pro-piece peptide in the treatment cancer and cancer metastasis.

Wikipedia References

Moshe Arditi Photo 5

Moshe Arditi

Control profile
Moshe A Arditi from Encino, CA, age ~68 Get Report